137 related articles for article (PubMed ID: 36642534)
1. Anti-protease levels in cystic fibrosis are associated with lung function, recovery from pulmonary exacerbations and may be gender-related.
Essilfie AT; Houston N; Maniam P; Hartel G; Okano S; Reid DW
Respirology; 2023 Jun; 28(6):533-542. PubMed ID: 36642534
[TBL] [Abstract][Full Text] [Related]
2. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
Weldon S; McNally P; McElvaney NG; Elborn JS; McAuley DF; Wartelle J; Belaaouaj A; Levine RL; Taggart CC
J Immunol; 2009 Dec; 183(12):8148-56. PubMed ID: 20007580
[TBL] [Abstract][Full Text] [Related]
3. Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions.
Hentschel J; Fischer N; Janhsen WK; Markert UR; Lehmann T; Sonnemann J; Böer K; Pfister W; Hipler UC; Mainz JG
J Cyst Fibros; 2015 May; 14(3):324-33. PubMed ID: 25286826
[TBL] [Abstract][Full Text] [Related]
4. A secretory leukocyte protease inhibitor variant with improved activity against lung infection.
Camper N; Glasgow AM; Osbourn M; Quinn DJ; Small DM; McLean DT; Lundy FT; Elborn JS; McNally P; Ingram RJ; Weldon S; Taggart CC
Mucosal Immunol; 2016 May; 9(3):669-76. PubMed ID: 26376365
[TBL] [Abstract][Full Text] [Related]
5. Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy.
Müller U; Hentschel J; Janhsen WK; Hünniger K; Hipler UC; Sonnemann J; Pfister W; Böer K; Lehmann T; Mainz JG
Mediators Inflamm; 2015; 2015():626530. PubMed ID: 26185365
[TBL] [Abstract][Full Text] [Related]
6. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
[TBL] [Abstract][Full Text] [Related]
7. Antibody response against Pseudomonas aeruginosa and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients.
Mauch RM; Hentschel J; Aanaes K; Barucha A; Nolasco da Silva MT; Levy CE; Høiby N; Mainz JG
Pediatr Pulmonol; 2020 Apr; 55(4):959-967. PubMed ID: 32022432
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.
Karandashova S; Kummarapurugu A; Zheng S; Kang L; Sun S; Rubin BK; Voynow JA
Pediatr Pulmonol; 2018 Jul; 53(7):872-880. PubMed ID: 29624923
[TBL] [Abstract][Full Text] [Related]
9. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
10. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
[TBL] [Abstract][Full Text] [Related]
11. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis.
Guyot N; Butler MW; McNally P; Weldon S; Greene CM; Levine RL; O'Neill SJ; Taggart CC; McElvaney NG
J Biol Chem; 2008 Nov; 283(47):32377-85. PubMed ID: 18799464
[TBL] [Abstract][Full Text] [Related]
12. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis.
Reid DW; Carroll V; O'May C; Champion A; Kirov SM
Eur Respir J; 2007 Aug; 30(2):286-92. PubMed ID: 17504792
[TBL] [Abstract][Full Text] [Related]
13. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
14. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.
Sagel SD; Wagner BD; Anthony MM; Emmett P; Zemanick ET
Am J Respir Crit Care Med; 2012 Nov; 186(9):857-65. PubMed ID: 22904182
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial peptides, disease severity and exacerbations in bronchiectasis.
Sibila O; Perea L; Cantó E; Shoemark A; Cassidy D; Smith AH; Suarez-Cuartin G; Rodrigo-Troyano A; Keir HR; Oriano M; Ong S; Vidal S; Blasi F; Aliberti S; Chalmers JD
Thorax; 2019 Sep; 74(9):835-842. PubMed ID: 31278172
[TBL] [Abstract][Full Text] [Related]
16. Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
Houston CJ; Alkhatib A; Einarsson GG; Tunney MM; Taggart CC; Downey DG
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38135443
[TBL] [Abstract][Full Text] [Related]
17. Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6.
Majka G; Mazurek H; Strus M; Ciszek-Lenda M; Szatanek R; Pac A; Golińska E; Marcinkiewicz J
Clin Exp Immunol; 2021 Sep; 205(3):391-405. PubMed ID: 34031873
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1.
Påhlman LI; Jögi A; Gram M; Mori M; Egesten A
BMC Pulm Med; 2015 Mar; 15():19. PubMed ID: 25851169
[TBL] [Abstract][Full Text] [Related]
19. A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation.
Chillappagari S; Müller C; Mahavadi P; Guenther A; Nährlich L; Rosenblum J; Rubin BK; Henke MO
J Cyst Fibros; 2016 May; 15(3):325-31. PubMed ID: 26526358
[TBL] [Abstract][Full Text] [Related]
20. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
